Sinclair Pharma

Press Release

22 April 2010

Syntopix Group plc


("Syntopix" or "the Company" or "the Group")





Syntopix announces agreement with Sinclair Pharma





Syntopix Group plc (AIM:SYN), the
company focused on topical antimicrobial innovations for products in
the medicine and consumer healthcare markets, is pleased to announce
that it has signed an agreement with Sinclair Pharma plc (LON:SPH)
("Sinclair"), the international specialty pharma company, to work
together on the identification of an antimicrobial compound to
synergise and augment the activity of a key product for Sinclair.





Sinclair is a leading skin and mouth
disease specialist with sales and marketing operations across Europe
and will work in conjunction with Syntopix to develop a product. Should
the collaboration result in a product that reaches commercialisation,
financial gains from the sales will be shared between the two companies.





Dr Stephen Jones, CEO of Syntopix, says:
"We are delighted to be entering into this collaboration with Sinclair.
I am very confident that its proprietary compound will be complemented
and enhanced by some of the compounds that Syntopix has been
identifying in this area over several years. We look forward to sharing
exciting compounds and technical expertise with the intention of
developing a market leading healthcare product."

Message from SPH CEO

"In January our underlying operations were profitable for the first
time, due to the combined benefits of the Flammazine acquisition and
cost saving programmes. I am very pleased that we have now built a
sustainable business model.

In no particular order, here are some but not all the reasons to be optimistic for Sinclair’s future:

1. Further value-creating deals are under evaluation and seem highly possible.

2. The emerging market opportunity for our dermatology portfolio offers a real upside to profit and revenues.

3. We have re-started the delmopinol development programme,
while discussions for an OTC Decapinol launch in the US are ongoing.

4. The supply chain is undergoing a process of reorganisation
and simplification, which should result in a considerable improvement
to the gross margin.

5. Italy’s turnaround in the past 12 months is remarkable. I am
also confident France will move back into growth later this year.

6. It is early days, but Flammazine is performing above
expectations and there appear to be several opportunities to expand the
product geographically and through line extensions.

7. It is also early days for Spain and Germany, but we have
good people and will continue to invest to create the scale required
for profitability.

Sinclair has entered an exciting new era. Thank you to all
shareholders for your confidence in Sinclair Pharma and to all
employees for your efforts in recent weeks. In the past year, Sinclair
has progressed to being well financed and now profitable. I am
optimistic for our future and confident that over the next 12 months we
will produce further dramatic improvement."


Chris Spooner

+15.15 %